Abstract: Embodiments of the present disclosure relate generally to expression of synthetic messenger RNA (mRNA) in target cells (e.g., a cardiac cell, such as for example and not limitation, a cardiomyocyte, a neuronal cell, a cell located within the eye, a pancreatic cell, a PSC, an IPSC, an ESC, and/or a PSC cardiomyocyte) in order to modulate and/or detect cell phenotype, and more specifically to use of a composition comprising (i) at least one (or a combination of) mRNA(s) encoding a differentiation factor, a transcription factor and/or a phenotype sensor; and (ii) a delivery vehicle, such as for example and not limitation, a cationic lipid, a polyethylenimine (PEI) derivative, a polymer, a polypeptide or peptide, a nanoparticle, or a lipid-based particle, wherein the composition is delivered to the target cell.

Abstract: Synthetic oligonucleotides are used to express opsins in cells, such as neurons and cardiomyocytes, for rapid induction of light-responsive electrophysiological behavior. Such induction can change the electrical properties of the cell. MEA analysis and use of voltage indicator proteins are described. Methods of testing drugs for their effect on electrical properties of the cell are described, along with methods for screening drugs that have an effect on a cell's electrical properties.

Abstract: This disclosure relates to binding agents specific for the envelope protein of a virus, e.g., lentivirus, wherein the binding agent is conjugated to a molecule with a radioisotope or positron-emitting radionuclide. In certain embodiments, the disclosure relates to methods of imaging a virus or other pathogen within the body of a subject using binding agents disclosed herein. In certain embodiments, the disclosure relates to methods of treating or preventing a viral or other pathogenic infection by administering pharmaceutical composition containing radioactive binding agents disclosed herein.